Velasof
Velasof (Sofosbuvir + Velpatasvir 400 + 100 mg) — Hetero generic of Epclusa. WHO-preferred first-line pan-genotypic HCV regimen.
✓ Ιατρικά ελεγμένο από Morgan Ellis — Ερευνητής Φαρμακευτικής · 8 χρόνια εμπειρία · Τελευταία αναθεώρηση: Μάιος 2026
Quick Answer
Velasof — sofosbuvir 400 mg + velpatasvir 100 mg fixed combination (Hetero Drugs). Pan-genotypic single-tablet regimen for chronic hepatitis C across all 6 genotypes — 12 weeks once daily. Cure rate ≥95% including genotype 3 and decompensated cirrhosis (with ribavirin). Generic of Gilead Epclusa.
Αυτό που λαμβάνετε με την MedsBase:
- WHO-GMP certified manufacturer
- Discreet plain-envelope packaging
- Παγκόσμια αποστολή
- Rated by 1,400+ customers (read reviews)
📦 Reshipment Assurance: if your order has not arrived 20 business days after dispatch, we reship it at no extra cost. Read the policy.
Γιατί να παραγγείλετε από τη MedsBase
Velasof ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
All DAA Hep C therapies carry an FDA black-box warning for hepatitis B virus reactivation in patients co-infected with HCV + HBV (which can be fulminant and fatal). Test for HBsAg and HBV DNA before starting any DAA regimen. If HBV-positive, hepatology must manage co-treatment or prophylactic anti-HBV therapy.
How it works
Two pan-genotypic DAAs in one tablet:
- Sofosbuvir — NS5B nucleotide polymerase inhibitor (chain terminator)
- Velpatasvir — second-generation NS5A inhibitor with broader coverage and higher barrier to resistance than ledipasvir
Velpatasvir has activity across all 6 HCV genotypes including G2 and G3, where ledipasvir-based regimens are weaker. The combination is the WHO-preferred first-line regimen for resource-limited settings (no genotype testing needed before treatment).
Velpatasvir absorption is pH-dependent. Avoid PPIs if possible; if needed, take the DAA tablet first thing in the morning with food, then take the PPI later. Antacids ≥4 hours separation.
Treatment-duration table
| Population | Regimen |
|---|---|
| All genotypes (1-6), treatment-naive, no cirrhosis | 12 weeks one tablet daily — pan-genotypic |
| All genotypes with compensated cirrhosis | 12 weeks one tablet daily |
| Treatment-experienced (any genotype, no cirrhosis) | 12 weeks one tablet daily |
| Decompensated cirrhosis (Child-Pugh B/C) | 12 weeks + ribavirin (specialist hepatology supervision) |
Sustained virologic response at 12 weeks post-treatment (SVR12) is the marker of cure — achieved in ~95-99% of patients across modern DAA regimens.
Important drug interactions
| Drug | Effect & action |
|---|---|
| Amiodarone + sofosbuvir | FDA warning — symptomatic bradycardia, deaths reported. Avoid combination. If unavoidable, in-hospital cardiac monitoring required. |
| PPIs (omeprazole, pantoprazole) | Reduce ledipasvir absorption (pH-dependent). Take ledipasvir-containing regimens with food and PPIs ≥4 hours apart, or use H2 blockers/antacids instead. Velpatasvir also pH-sensitive — same advice. |
| Rifampicin, rifabutin | Strong CYP3A4 + P-gp inducers — significantly reduce DAA levels. Avoid combination. |
| St John’s wort | CYP3A4 induction — reduces DAA levels and risks treatment failure. Avoid throughout therapy. |
| Phenytoin, carbamazepine, oxcarbazepine | Anticonvulsant inducers — significantly reduce DAA levels. Switch to non-inducing antiepileptic (lamotrigine, levetiracetam) before starting Hep C therapy. |
| Statins (rosuvastatin, atorvastatin) | Variable rises in statin levels. Use lowest dose; rosuvastatin generally avoided with sof+vel; atorvastatin acceptable at low dose. |
| Warfarin | INR can fluctuate as the liver recovers during DAA therapy. Monitor INR weekly until stable. |
| HIV antiretrovirals | Tenofovir + ledipasvir — increased tenofovir exposure; monitor renal function. Efavirenz reduces velpatasvir levels — avoid combination. HCV-HIV co-infection always needs ID/hepatology specialist input. |
Συχνές Ερωτήσεις
What is the cure rate?
Modern DAA regimens achieve sustained virologic response (SVR12) — undetectable HCV RNA at 12 weeks post-treatment, considered cure — in 95-99% of patients across genotypes. Cirrhosis, prior treatment failure, and HCV/HIV co-infection slightly reduce response rates.
What is SVR12?
Sustained Virologic Response at 12 weeks post-treatment. After completing a 12-week DAA course, HCV RNA is checked at 12 weeks after the last dose. Undetectable = cure. Late relapse beyond SVR12 is <1%.
Will I need a follow-up test?
Yes. HCV RNA at the end of treatment + at 12 weeks post-treatment confirms SVR12. Liver biochemistry and FibroScan/imaging at 6-12 months in cirrhotic patients to assess regression. Even after cure, screen for hepatocellular carcinoma every 6 months if cirrhosis is established.
What about hepatitis B?
All DAAs carry an FDA black-box warning for HBV reactivation in HCV+HBV co-infected patients. Test HBsAg and HBV DNA before starting. If HBV-positive, hepatology must coordinate.
Can I drink alcohol?
Avoid alcohol throughout treatment and ideally for 6-12 months after. Active alcohol use does not preclude DAA therapy but worsens long-term liver outcomes regardless of HCV status.
Pregnancy?
Sofosbuvir is FDA pregnancy category B (no human teratogenicity data; animal data reassuring). Most DAAs lack pregnancy data. Contraception during therapy is standard. Ribavirin (where used as adjunct) is strongly teratogenic — both partners must use contraception during ribavirin therapy and 6 months after.
Side effects?
Modern DAAs are generally well tolerated. Common: fatigue, headache, nausea, insomnia. Less common: rash, diarrhoea. Treatment-limiting side effects are rare.
Generic vs branded — does it matter?
Indian generic DAAs are manufactured under voluntary licences from Gilead (Sovaldi, Harvoni, Epclusa), AbbVie, and BMS. They are bioequivalent and have the same molecule. Multiple real-world studies (CT2, Plus-Asia) show equivalent SVR12 rates to branded products.
Drug interactions to watch?
Most important: amiodarone + sofosbuvir (bradycardia black-box), rifampicin (kills DAA levels), PPIs (reduce ledipasvir/velpatasvir), HIV ARV adjustments needed in co-infection. Always disclose all medications including herbal/OTC.
After cure — can I get HCV again?
Yes. SVR clears the current infection but does not provide future immunity. Re-infection through new exposures (IV drug use, unsafe medical procedures, MSM with HIV co-infection) is possible. Counsel on prevention and offer HCV RNA testing at any new risk exposure.
Other Hepatitis C Medications
- Ledifos — sofosbuvir + ledipasvir — genotype 1/4/5/6 alternative
- Hepcvir L — sofosbuvir + ledipasvir — Cipla brand
- Natdac — daclatasvir for sofosbuvir-partner regimens
- MyHep — sofosbuvir 400 mg monotherapy backbone
- Hepcinat — sofosbuvir 400 mg — Natco brand
More options in Hepatitis Medication
Ταξινομημένα σύμφωνα με τον όγκο παραγγελιών στο MedsBase — τι επιλέγουν άλλοι πελάτες σε αυτήν την κατηγορία.
| Ισχύς | 400 mg + 100 mg |
|---|---|
| Ποσότητα | 28 Tablet/s, 56 Tablet/s, 84 Tablet/s |
| Pharma Form | Tablet/s |
| Manufacturer | Hetero Drugs |
| Treatment | Chronic hepatitis C virus (HCV) infection |
| Generic Brand | Sofosbuvir & Velpatasvir |
Velasof
Ερωτήσεις & Απαντήσεις
Velasof
Σχετικά προϊόντα
Κριτικές
Δεν υπάρχουν ακόμη κριτικές